Madhavi
22 Jul 2025
Collaboration aims to accelerate translational research and advance transformative therapies in key therapeutic areas.
Abhinavayan Biotech is pleased to announce a strategic and scientific partnership with PNB Vesper Life Sciences, marking a significant step forward in advancing transformative therapies and strengthening India’s role in global biotech innovation.
The collaboration is designed to combine Abhinavayan’s expertise in scientific evaluation and development strategy with PNB Vesper’s strong clinical pipeline, with the shared goal of redefining patient care and therapeutic standards. Together, the two organizations will focus on accelerating innovation through rigorous science, coordinated execution, and agile collaboration.
As part of this partnership, future initiatives will include:
Molecule-specific technical evaluations
Validation of molecular mechanisms of action
Coordinated pre-clinical study planning and oversight with CROs/CDMOs
Re-purposing of clinical assets for novel therapeutic indications
Development of a strategic scientific roadmap and risk-mitigation framework
Guidance on intellectual property positioning and licensing preparedness
Creation of scientific dossiers for licensing and regulatory communications
Strategic recommendations for key stakeholders
Technical support for commercial licensing or partnerships
Expressing enthusiasm for the collaboration, the Abhinavayan team said, “This partnership epitomizes our mutual dedication to translating bold science into meaningful therapies. Together with PNB Vesper, we aspire to unlock the potential of promising molecules and deliver innovations that matter to patients.”
Abhinavayan Biotech extends its appreciation to the PNB Vesper team for this collaboration and looks forward to advancing programs that bring impactful therapies closer to those in need.